What CJC-1295 changed in people and animals

What rat tests found about CJC-1295

CJC-1295 joins receiving spots on cells in your growth gland. The compound increases how much growth hormone those cells make and release ^[2]. Then your liver increases production of a second hormone supporting growth ^[3]. That's what the blood tests follow, without proving a health benefit.

Researchers tested CJC-1295 and related compounds in rats. Four changes protected the compound's chain from breaking down. A separate link joined the chain with the blood protein albumin. The chain stayed intact longer, and the protein kept it in blood.

The linked compound produced a 4-fold rise in total growth-hormone release. That means researchers measured four times as much release over two hours. Beyond 72 hours, blood still contained the linked compound ^[2]. You can't treat those rat results as benefits proved in people.

What human blood tests changed without proving benefits

Healthy adults aged 21-61 each received one injection under their skin. Researchers used 30 or 60 micrograms per kilogram each person weighed. Bigger amounts caused bigger growth-hormone rises lasting several days ^[3]. You don't get a proven treatment amount from those tests.

CJC-1295 also made the liver produce more of its growth-supporting hormone. After repeated shots, researchers measured higher levels for up to 28 days. That's a lasting change in blood, without proof of lasting benefit. Your strength, fat loss, and lifespan weren't established by that finding.

Another study tested 11 healthy young men given CJC-1295. Proteins carrying fats fell, while pieces of albumin and infection-fighting proteins rose ^[5]. Those rises went along with the liver's growth-supporting hormone rise. You don't learn whether the men felt or functioned better from those tests.

Blood proteins can help researchers recognize a hormone change. Think of a fuel gauge that doesn't test how the car drives. CJC-1295 trials haven't proved the broader benefits people discuss. You still need evidence about health, beyond changes in blood.

What the hormone spurts kept doing after CJC-1295

Men received a 60-or-90-microgram/kg shot beneath their skin. The amount in micrograms depended on the weight in kilograms. Their growth hormone averaged about 46% higher, with raised levels between brief spurts. Their liver's growth-supporting hormone was about 45% higher a week later ^[1].

The timing and size of spurts didn't change. Other hormone-releasing compounds changed the spurts in different ways ^[10]. Mice lacking the natural hormone that starts release grew normally with daily CJC-1295 ^[4]. Giving shots farther apart helped those mice less, without establishing your treatment schedule.

What makes CJC-1295 leave blood slowly

The blood protein albumin carries CJC-1295 once the added DAC link joins them. Together, the compound and protein weigh about 66 kilodaltons (units used for tiny substances). That weight concerns the joined substance, rather than an amount to take. Albumin leaves blood slowly, so the linked compound leaves your blood slowly too.

Healthy adults received repeated shots of this longer-lasting form. Higher levels of the liver's growth-supporting hormone lasted up to 28 days ^[3]. That tells you how long a blood-test change lasted. You can't infer that a health benefit lasted equally long.

The shorter form, 'Modified GRF 1-29,' also resists breakdown. But no link lets this shorter form travel with albumin. You have minutes to hours of action with this form, instead of days. Your CJC-1295 DAC vs no-DAC comparison explains why the findings need separate evidence.

What related compounds do beyond CJC-1295

CJC-1295 belongs to a group copying the body's growth-hormone-releasing hormone. That natural hormone makes growth hormone come out of your gland. Sermorelin and tesamorelin also copy the hormone's action. You can't assume these related compounds share benefits or approval.

2024/2025 review work examined the hormone and these copies ^[14]. The review described how the compounds act and their research limits. For a fat-distribution problem linked with HIV, tesamorelin has FDA approval. That approval doesn't extend to CJC-1295 or your possible uses.

Other experiments found better wound healing, without establishing treatment benefits in people ^[11]. Another treatment helped weak bones and damaged skin in aged mice ^[12]. A human study found changed hormone spurts and how well insulin lowered blood sugar ^[13]. The study summary doesn't say whether blood sugar rose or fell, or establish CJC-1295 benefits for you.

What the unfinished human research leaves unanswered

Phase 1 studies (first tests in people) checked hormone changes. Healthy volunteers had higher levels while the short hormone spurts continued ^[3][1]. The researchers showed lasting changes in their blood tests. You don't yet know whether those changes improve daily life.

ConjuChem later stopped a Phase 2 study testing a possible treatment. People living with HIV took part because they had excess deep belly fat. You may recognize the longer-lasting CJC-1295 form here by its DAC link. That program didn't go on to establish a treatment.

CJC-1295 hasn't had large trials establishing benefits for healthy adults. Nor have long studies settled the compound's safety. Less fat, quicker recovery, and slower aging remain unproved claims. CJC-1295 still lacks human treatment approval, regardless of those claims.

Scientists found CJC-1295 in a seized drug mixture of unknown contents ^[6]. That finding concerns detection during work against banned sports drugs. Detecting a compound doesn't show you that using it is safe. The missing long-term tests still leave your health questions unanswered.